CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.75%. Read on to learn why. Crispr Therapeutics AG has experienced a notable 7.75% increase in ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

CRISPR Therapeutics stock has slipped 20% from its 2025 high in July, and Wood took advantage of that to add more shares of ...